 Minerva Neurosciences Inc NASDAQ: NERV received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. The agency cited concerns related to the applicability of the results of the Phase 2b. 